Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels

Haematologica

Volumn 99, Issue 12, 2014, Pages 1876-1884

  Rossi, Francesca ^a   Perrotta, Silverio ^a   Bellini, Giulia ^a   Luongo, Livio ^a   Tortora, Chiara ^a   Siniscalco, Dario ^a   Francese, Matteo ^a   Torella, Marco ^a   Nobili, Bruno ^a   Di Marzo, Vincenzo ^b,c   Maione, Sabatino ^a,c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CNR   (Italy)

^c Endocannabinoid Research Group   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CATHEPSIN K; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ENDOCANNABINOID; FATTY ACID AMIDASE; FERRITIN; LIPOPROTEIN LIPASE; PHOSPHOLIPASE D; RESINIFERATOXIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE; VANILLOID RECEPTOR 1; VIMENTIN; ACID PHOSPHATASE; BIOLOGICAL MARKER; IRON CHELATING AGENT; ISOENZYME; MESSENGER RNA; TARTRATE-RESISTANT ACID PHOSPHATASE; TRPV1 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ADULT; ARTICLE; BETA THALASSEMIA; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; CHELATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; IRON CHELATION; IRON OVERLOAD; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THALASSEMIA MAJOR; UPREGULATION; WESTERN BLOTTING; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; COMPLICATION; CYTOLOGY; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS;

ACID PHOSPHATASE; ADULT; BETA-THALASSEMIA; BIOMARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CATHEPSIN K; CELLS, CULTURED; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; ISOENZYMES; MALE; OSTEOCLASTS; OSTEOPOROSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRPV CATION CHANNELS;

EID: 84919343513     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.104463     Document Type: Article

References (50)

1. Skordis N, Toumba M. Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects. Pediatr Endocrinol Rev. 2011;8(Suppl 2):300-6.
2. Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with beta thalassemia major. Bone. 2011;48(3):425-32.
3. Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an overview. J Osteoporos. 2010;2010:537673.
4. Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis. Ann NY Acad Sci. 2010;1202:237-43.
5. Vogiatzi MG, Macklin EA, Fung EB, Cheung AM, Vichinsky E, Olivieri N, et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res. 2009;24 (3):543-57.
6. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol. 2004;127(2):127-39.
7. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, et al. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol. 2000;111(2):461-6.
8. Chatterjee R, Shah FT, Davis BA, Byers M, Sooranna D, Bajoria R, et al. Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to 18 pamidronate in beta-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol. 2012;159 (4):462-71.
9. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, et al. Bone histomorphometry in children and adolescents with beta-thalassemia disease: ironassociated focal osteomalacia. J Clin Endocrinol Metab. 2003;88(8):3966-72.
10. Valenti L, Varenna M, Fracanzani AL, Rossi V, Fargion S, Sinigaglia L. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int. 2009;20(4):549-55.
11. Isomura H, Fujie K, Shibata K, Inoue N, Iizuka T, Takebe G, et al. Bone metabolism and oxidative stress in postmenopausal rats with iron overload. Toxicology. 2004;197 (2):93-100.
12. Maggio A, Filosa A, Vitrano A, Aloj G, Kattamis A, Ceci A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 2011;47(3):166-75.
13. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr. 1996;155 (5):368-72.
14. Voskaridou E, Kyrtsonis MC, Terpos E, Skordili M, Theodoropoulos I, Bergele A, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol. 2001;112(1):36-41.
15. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol. 2003;123(4):730-7.
16. Chatterjee R, Katz M, Bajoria R. Use of hormone replacement therapy for correction of high turnover bone disease in hypogonadal beta-thalassemia major patients presenting with osteoporosis: comparison with idiopathic premature ovarian failure. Hemoglobin. 2011;35(56):6538.
17. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol. 2000;111(3):902-7.
18. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res. 2004;19(5):722-7.
19. Voskaridou E, Terpos E. Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. Eur J Haematol. 2005; 74(4):359-61.
20. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, et al. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 2006;91(9):1193-202.
21. Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, et al. The "lively" cytokines network in beta-thalassemia major-related osteoporosis. Bone. 2007;40 (6):1588-94.
22. Rossi F, Bellini G, Luongo L, Torella M, Mancusi S, De Petrocellis L, et al. The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. Bone. 2011;48(5):997-1007.
23. Ljusberg J, Wang Y, Lang P, Norgard M, Dodds R, Hultenby K, et al. Proteolytic excision of a repressive loop domain in tartrateresistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem. 2005;280(31): 28370-81.
24. Bab I, Zimmer A, Melamed E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med. 2009;41(8):560-7.
25. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol. 2008;20 (Suppl 1):69-74.
26. Idris AI, van 't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 2005;11(7): 774-9.
27. Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, et al. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab. 2009;10(2):139-47.
28. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 2006;103(3):696-701.
29. Idris AI, Sophocleous A, Landao-Bassonga E, van't Hof RJ, Ralston SH. Regulation of bone mass, osteoclast function, and ovariectomy- induced bone loss by the type 2 cannabinoid receptor. Endocrinology. 2008;149(11):5619-26.
30. Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S, et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone. 2009; 44(3):476-84.
31. Idris AI, Landao-Bassonga E, Ralston SH. The TRPV1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo. Bone. 2010;46 (4):1089-99.
32. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-5.
33. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series. 1994;843:1-129.
34. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochemical J. 1997;322(Pt 2):671-7.
35. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530-4.
36. Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, et al. Markers of bone metabolism in eugonadal female patients with beta-thalassemia major. Pediatr Hematol Oncol. 2007;24(7): 481-91.
37. Chatterjee R, Bajoria R. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin. 2009;33 (Suppl 1):S136-8.
38. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22 (23):2171-9.
39. Hankins JS, McCarville MB, Loeffler RB, Smeltzer MP, Onciu M, Hoffer FA, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood. 2009; 113(20):4853-5.
40. Rossi F, Bellini G, Luongo L, Mancusi S, Torella M, Tortora C, et al. The 17- betaoestradiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression. Pharmacol Res. 2013;68(1):7-15.
41. Rossi F, Bellini G, Alisi A, Alterio A, Maione S, Perrone L, et al. Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. PloS One. 2012;7(8):e42259.
42. Rossi F, Bellini G, Tolone C, Luongo L, Mancusi S, Papparella A, et al. The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. Pharmacol Res. 2012;66 (1):88-94.
43. Izzo AA, Piscitelli F, Capasso R, Marini P, Cristino L, Petrosino S, et al. Basal and fasting/ refeeding-regulated tissue levels of endogenous PPAR-alpha ligands in Zucker rats. Obesity. 2010;18(1):55-62.
44. Straiker A, Wager-Miller J, Hutchens J, Mackie K. Differential signalling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurones. Br J Pharmacol. 2012;165(8):2660-71.
45. Laprairie RB, Kelly ME, Denovan-Wright EM. The dynamic nature of type 1 cannabinoid receptor (CB(1)) gene transcription. Br J Pharmacol. 2012;167(8):1583-95.
46. El Rawas R, Thiriet N, Nader J, Lardeux V, Jaber M, Solinas M. Early exposure to environmental enrichment alters the expression of genes of the endocannabinoid system. Brain Res. 2011;1390:80-9.
47. Hong S, Zheng G, Wu X, Snider NT, Owyang C, Wiley JW. Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. Gastroenterology. 2011;140(2):627-37. e4.
48. Sooampon S, Manokawinchoke J, Pavasant P. Transient receptor potential vanilloid-1 regulates osteoprotegerin/RANKL homeostasis in human periodontal ligament cells. J Periodontal Res. 2013;48(1):22-9.
49. Kramer JL, Baltathakis I, Alcantara OS, Boldt DH. Differentiation of functional dendritic cells and macrophages from human peripheral blood monocyte precursors is dependent on expression of p21 (WAF1/CIP1) and requires iron. Br J Haematol. 2002;117 (3):727-34.
50. Furukawa Y. Cell cycle control during hematopoietic cell differentiation. Hum Cell. 1997;10(3):159-64.